HDAC9 and glioblastoma: Moreover, Chinnaiyan et al. found IGFBP-5 as a possible predictive protein marker for combined treatment with bevacizumab, HDAC inhibitor vorinostat, and irinotecan in a limited study (n = 10 recurrent glioblastoma patients) [242].